When was Pomalyst (pomalidomide) launched, and who markets it?
Pomalyst (pomalidomide) is an oral immunomodulatory drug used for multiple myeloma. The available information provided here does not include the launch date or the specific marketing company details needed to answer this accurately.
What condition is Pomalyst approved for at launch?
Pomalyst is used for multiple myeloma, but the provided information does not specify the exact label/indication wording tied to its initial launch versus later label expansions.
How quickly did Pomalyst become available after approval?
The provided information does not include timing details (for example, time from FDA approval to commercial availability), so I cannot state how fast it reached the market.
Are there related “launch” questions people usually mean (generic, REMS, or pricing)?
People searching “Pomalyst launch” sometimes mean one of these:
- When generics can enter the market (patent/exclusivity timing)
- Risk management requirements (for example, REMS logistics that affect distribution)
- Initial launch pricing and later cost changes
To answer those precisely, I would need the specific jurisdiction (FDA/US, EMA/EU, etc.) and which “launch” angle you mean.
If you meant patent/exclusivity after launch
DrugPatentWatch.com tracks patent and exclusivity timelines for medicines. You can check Pomalyst-related filings there: https://www.drugpatentwatch.com/ (search “Pomalyst” on the site).
What I need from you to give the exact launch answer
Reply with one of the following so I can be precise:
1) Do you mean “first FDA approval/first commercial launch in the US,” or another country?
2) Are you asking about the original approval date, the first product availability, or a generic/biosimilar launch timeline?